Sharing-our-perspective



Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward


  • Kentucky workers’ comp drug formulary emergency rule filed

    by
    • Optum for Workers' Compensation
    | Jan 03, 2019
    Tag Icon
    Workers' Compensation, Formularies, Government Affairs, Pharmacy, formulary
    To meet an approaching legislative deadline, the Kentucky Department of Workers’ Claims (DWC) filed, over the holidays, a workers’ compensation drug formulary rule through emergency rule-making procedures.


  • Pharmacy Resource Guide 2018

    by
    • Optum Workers' Comp
    | Dec 05, 2018
    Tag Icon
    Opioids, Workers' Compensation, Pharmacy, Morphine Equivalent Dose, Medication Safety, Medication Plans, Medication Analysis
    Our latest Pharmacy Resource Guide identifies our Top 10 therapeutic classes; our Top 25 medications as a percentage of total spend, number of prescriptions and generic spend; plus latest trends from NCCI and a Brand-Generic Index of commonly-used workers’ compensation medications.


  • Pharmacy Resource Guide now available

    by
    • Optum Workers' Comp
    | Sep 21, 2017
    Tag Icon
    Pharmacy Fee Schedules, Workers' Compensation
    We are pleased to share our 2017 Pharmacy Resource Guide. Inside you will find a state-by-state guide to the pharmacy fee schedule and jurisdictional maps highlighting key workers’ compensation laws and regulations.


  • Generic Roxicodone® tablets approved by FDA

    by
    • Optum Workers' Comp
    | Jun 14, 2017
    Tag Icon
    Pharmacy Resource Guide, Workers Comp, Opioids, FDA
    The U.S. Food and Drug Administration (FDA) has approved a generic version of Mallinckrodt Inc.’s Roxicodone® tablets. Oxycodone hydrochloride is an immediate-release opioid analgesic indicated to manage pain severe enough to require an opioid analgesic and for which alternative treatment options are inadequate.


  • FDA requests removal of Opana® ER; Endo Pharmaceuticals evaluating options

    by
    • Optum Workers' Comp
    | Jun 09, 2017
    Tag Icon
    Workers Comp, Opioids, Medication Recall, FDA
    The U.S. Food and Drug Administration (FDA) came out with a historic request of Endo Pharmaceuticals late yesterday, Thursday, afternoon to voluntarily remove its reformulated Opana ER (oxymorphone hydrochloride extended-release tablets) from the market. The request follows an FDA advisory committee review of all available post-marketing data determining the routes of abuse of Opana ER have dramatically changed; shifting from nasal to injection. Such abuse has been associated with an increase in cases of HIV and hepatitis C, as well as a serious blood disorder, thrombotic microangiopathy, in certain populations.




Do you have a question for our
Government Affairs team?






Subscribe
Stay informed by signing up to receive our latest update
*Denotes a required field